Pleiotropic effects of niacin: current possibilities for its clinical use

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61389013%3A_____%2F16%3A00466227" target="_blank" >RIV/61389013:_____/16:00466227 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11110/16:10329243

Result on the web

<a href="http://dx.doi.org/10.1515/acph-2016-0043" target="_blank" >http://dx.doi.org/10.1515/acph-2016-0043</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1515/acph-2016-0043" target="_blank" >10.1515/acph-2016-0043</a>

Result language

angličtina

Original language name

Pleiotropic effects of niacin: current possibilities for its clinical use

Original language description

Niacin was the first hypolipidemic drug to significantly reduce both major cardiovascular events and mortality in patients with cardiovascular disease. Niacin favorably influences all lipoprotein classes, including lipoprotein[a],and belongs to the most potent hypolipidemic drugs for increasing HDL-C. Moreover, niacin causes favorable changes to the qualitative composition of lipoprotein HDL. In addition to its pronounced hypolipidemic action, niacin exerts many other, non-hypolipidemic effects (e.g., antioxidative, anti-inflammatory, antithrombotic), which favorably influence the development and progression of atherosclerosis. These effects are dependent on activation of the specific receptor HCA2. Recent results published by the two large clinical studies, AIM-HIGH and HPS2-THRIVE, have led to the impugnation of niacin’s role in future clinical practice. However, due to several methodological flaws in the AIM-HIGH and HPS2-THRIVE studies, the pleiotropic effects of niacin now deserve thorough evaluation. This review summarizes the present and possible future use of niacin in clinical practice in light of its newly recognized pleiotropic effects.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

CD - Macromolecular chemistry

OECD FORD branch

—

Project

<a href="/en/project/FR-TI4%2F638" target="_blank" >FR-TI4/638: Development of new sustained release formulation of nicotinic acid</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2016

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Acta Pharmaceutica

ISSN

1330-0075

e-ISSN

—

Volume of the periodical

66

Issue of the periodical within the volume

4

Country of publishing house

HR - CROATIA

Number of pages

21

Pages from-to

449-469

UT code for WoS article

000386863500001

EID of the result in the Scopus database

2-s2.0-84992623004